Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15327020 | 0.83 | HCRTR1 (0.61) | HCRTR1HCRTR2 | |
| SCHEMBL9977741 | 0.82 | HCRTR1 (0.56) | HCRTR1HCRTR2SCN9ADRD2CCNT1 | |
| SCHEMBL16812737 | 0.81 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL16812732 | 0.81 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL15604647 | 0.79 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL15604599 | 0.79 | HCRTR1 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL17274051 | 0.78 | PDE10A (0.49) | DRD2BRD4CKS1BSKP1SKP2 | |
| SCHEMBL9977899 | 0.78 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL9977806 | 0.76 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL1632156 | 0.76 | NAMPT (0.44) | DRD2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-24 | — | — | US | disclosed |
| WO-2012081692-A1 | PYRAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281465-A1 | PYRAZOLE DERIVATIVE | HCRTR1, HCRTR2, NPY4R | HCRTR1 1/4885HCRTR2 2/4885SCN9A 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.